Calculating comorbidity-adjusted life expectancy could help physicians determine whether to continue or cease cancer screening in elderly patients, according to a study published Nov. 18 in Annals of Internal Medicine.
The American Society of Clinical Oncology (ASCO) has released its top five list of tests, procedures, and treatments whose common use and clinical value are not supported by available evidence as part of the American Board of Internal Medicine’s Choosing Wisely Campaign.
After years of steady increase, colorectal cancer screening rates may be leveling off, according to the Centers for Disease Control and Prevention’s (CDC’s) latest “Vital Signs” report released online Nov. 5. The report found that 23 million people between the ages of 50 and 75 years old are not getting the testing recommended by the United States Preventive Services Task Force (USPSTF).
Undergoing a pretreatment PET/CT scan has shown to have more predictive value than conventional follow-up protocol for colorectal cancer with metastases to the liver and could be the case for other cancers, according to a study published Oct. 17 in the Journal of Nuclear Medicine.